Investment Stage

Focus Areas

About Investor

Daniel Estes is General Partner at Frazier Life Sciences (FLS) in San Diego, California, one of the leading biotech and pharmaceutical venture capital firms in the world. FLS manages $6.9B+ in assets under management (as of December 31, 2025) across venture and public strategies, with its latest fund — a $1.3 billion oversubscribed venture fund — closed in July 2025. The firm has 9 Partners, offices in Palo Alto (HQ), San Diego, Boston, and Seattle, has created 25+ companies since 2015, achieved 50+ IPOs and M&As representing $75B+ in cumulative value, and helped advance 75+ FDA-approved drugs through portfolio companies. FLS focuses exclusively on novel therapeutics from seed to public markets. Portfolio companies include Callio Therapeutics ($190M Series A, March 2025), Hillstar Bio ($67M Series A, March 2025), Alesta Therapeutics ($67M Series A, January 2025), Bluejay Therapeutics, Sudo Biosciences, Radionetics Oncology, and Hummingbird Bioscience; recent exits include Tubulis (Gilead acquisition, April 2026), Halda Therapeutics (Johnson & Johnson, November 2025), and Verona Pharma (Merck, October 2025).